Phaseline

Targets › IL12RB2

IL12RB2 (Interleukin-12 receptor subunit beta-2): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Receptor for interleukin-12. This subunit is the signaling component coupling to the JAK2/STAT4 pathway. (UniProt, Q99665)

Open in Phaseline: the race on IL12RB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kangabio AUSTRALIAKGX101
Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion
IL12, IL12RB1, IL12RB2Phase 1Advanced or Metastatic Solid TumorsJan 2027

Conditions

Advanced or Metastatic Solid Tumors (2)

Modalities

mixed (1)

Companies

Kangabio AUSTRALIA (1)

Related targets

IL12 (1) IL12RB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.